- Home
- ACRS vs SOPH Comparison
ACRS vs SOPH Comparison
Compare ACRS & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | SOPH |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.2M | 367.7M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACRS | SOPH |
|---|---|---|
| Price | $3.19 | $4.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $9.75 | $7.00 |
| AVG Volume (30 Days) | ★ 3.1M | 361.7K |
| Earning Date | 02-23-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $15,742,000.00 | ★ $73,297,000.00 |
| Revenue This Year | N/A | $18.48 |
| Revenue Next Year | N/A | $15.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.66 |
| 52 Week Low | $1.05 | $2.58 |
| 52 Week High | $4.89 | $5.70 |
Technical Indicators
Market Signals| Indicator | ACRS | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 44.65 |
| Support Level | $3.25 | $4.61 |
| Resistance Level | $3.78 | $5.06 |
| Average True Range (ATR) | 0.25 | 0.30 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 13.52 | 20.83 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.